Please assess the completion status of the following clinical trial:

Trial Title: Intraprostatic MAXimal Simultaneous Boost

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have histologically proven adenocarcinoma of the prostate.~2. Registration must occur within 26 weeks of biopsy.~3. History and physical examination (including digital rectal examination (DRE)) within 8 weeks prior to registration.~4. Patients must have intermediate risk prostate cancer, as defined by:~   * PSA ≤ 20 ng/ml,~  * Gleason ≤ 7,~  * Stage ≤ T2c, and~  * Do not meet criteria for low-risk prostate cancer (Low-risk = All of: PSA ≤ 10 + Gleason ≤ 6 + stage ≤ T2b)~5. Patients must have the following blood tests within two weeks of registration:~   * Prostate specific antigen (PSA), testosterone (TTT), complete blood count (CBC), electrolytes, creatinine.~  * Patients with values for one or more of these tests (not including PSA) that fall outside the normal range will need to be reviewed by the oncologist to determine their eligibility for this study.~6. Patients must have an estimated life expectancy of at least 10 years.~7. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2.~8. Patients must have no contraindications to high dose pelvic irradiation.~9. Patients must not have received prior radiation therapy to the pelvis.~10. Patients must have no history of inflammatory bowel disease.~11. Patients must not have received prior hormonal therapy or chemotherapy.~12. Patients must not have any hormonal therapy planned as part of the therapeutic intervention.~13. Patients must have no contraindication to MRI scanning.~14. Patients should not have an artificial hip~15. Patients should not have a body mass index (BMI) of \> 32. Note: BMI = weight in kg ÷ (height in metres)2~Exclusion Criteria:~1. Subjects that do not meet inclusion criteria.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMAX (Type: OTHER): There is only one arm in this study.~Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~* The prescription dose will be 73.7 Gy in 28 fractions.~* A simultaneous intraprostatic maximal simultaneous boost will be given to as much of the CTV as possible without contravening OAR dose constraints.

Based on this trial design, predict the completion outcome and termination type (if applicable).